Tumor Heterogeneity in Breast Cancer

2016 ◽  
pp. 121-132
Author(s):  
Sunil Badve
Keyword(s):  
Breast Cancer ◽  
Tumor Heterogeneity

scholarly journals Patient-Specific Network for Personalized Breast Cancer Therapy with Multi-Omics Data

Entropy ◽  
2021 ◽  
Vol 23 (2) ◽  
pp. 225
Author(s):  
Claudia Cava ◽  
Soudabeh Sabetian ◽  
Isabella Castiglioni
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Protein Interaction Network ◽  
Copy Number ◽  
Tumor Heterogeneity ◽  
Copy Number Alteration ◽  
Interaction Network ◽  
Computational Approach ◽  
Patient Specific ◽  
Basal Breast Cancer

The development of new computational approaches that are able to design the correct personalized drugs is the crucial therapeutic issue in cancer research. However, tumor heterogeneity is the main obstacle to developing patient-specific single drugs or combinations of drugs that already exist in clinics. In this study, we developed a computational approach that integrates copy number alteration, gene expression, and a protein interaction network of 73 basal breast cancer samples. 2509 prognostic genes harboring a copy number alteration were identified using survival analysis, and a protein–protein interaction network considering the direct interactions was created. Each patient was described by a specific combination of seven altered hub proteins that fully characterize the 73 basal breast cancer patients. We suggested the optimal combination therapy for each patient considering drug–protein interactions. Our approach is able to confirm well-known cancer related genes and suggest novel potential drug target genes. In conclusion, we presented a new computational approach in breast cancer to deal with the intra-tumor heterogeneity towards personalized cancer therapy.

scholarly journals Is There Any Rationale for Detecting Hormone Receptor/HER2 Status with Rebiopsy Without Progression Upfront Metastatic Breast Cancer? with 2 Cases

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Duman BB ◽  
Cil T
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Maintenance Therapy ◽  
Hormone Receptor ◽  
Tumor Heterogeneity ◽  
Hormone Receptors ◽  
Triple Negative ◽  
Neoadjuvant Treatment ◽  
Metastatic Breast ◽  
Her2 Overexpression

Alteration of biomarkers is well-documented in breast cancer at locoregional recurrence or metastasis attributed to tumor heterogeneity and change in biology. There is some data about discordance between primary and metastatic sites. At the same time hormone, receptor status can change after neoadjuvant treatment and at the time of recurrence. Metastatic breast cancer without progression or recurrence after the targeted chemotherapy combination for planning maintenance therapy in Human epidermal growth factor receptor 2 (HER2) overexpression positive hormone receptors positive or triple-negative patient after chemotherapy. In guidelines, the time of rebiopsy has no exact time, if the time of biopsy is usually after the progression of the tumor. We presented cases in which we detected different hormone receptor statuses from the beginning without progression and before deciding on maintenance therapy. This subject is important for deciding therapy in the aspect of heterogeneous tumors like breast cancer. The important decision of rebiopsy time is debate. In this aspect, these two cases are important examples for these kinds of patients tumor heterogeneity in breast cancer is one of the most widely known entities. We found that two patients, one of whom was estrogen progesterone receptor negative HER2 3 (+++) at the time of diagnosis and the other who was triple negative at the time of diagnosis, had positive hormone receptors in the re-biopsies without progression. We aimed to discuss the tumor heterogeneity and timing of rebiopsy in breast cancer in the light of two cases.

scholarly journals Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Govindasamy-Muralidharan Karthik ◽  
Mattias Rantalainen ◽  
Gustav Stålhammar ◽  
John Lövrot ◽  
Ikram Ullah ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Heterogeneity ◽  
Molecular Profiling ◽  
Limited Impact

scholarly journals Tumor Heterogeneity Correlates with Less Immune Response and Worse Survival in Breast Cancer Patients

2019 ◽  
Vol 26 (7) ◽  
pp. 2191-2199 ◽  
Author(s):  
Kerry-Ann McDonald ◽  
Tsutomu Kawaguchi ◽  
Qianya Qi ◽  
Xuan Peng ◽  
Mariko Asaoka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune Response ◽  
Cancer Patients ◽  
Tumor Heterogeneity ◽  
Breast Cancer Patients

scholarly journals Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer

2019 ◽  
Vol 146 (5) ◽  
pp. 1359-1368 ◽  
Author(s):  
Fei Ma ◽  
Yanfang Guan ◽  
Zongbi Yi ◽  
Lianpeng Chang ◽  
Qiao Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Tumor Heterogeneity ◽  
Therapeutic Response ◽  
Metastatic Breast

How to study and overcome tumor heterogeneity with circulating biomarkers: The breast cancer case

2017 ◽  
Vol 44 ◽  
pp. 106-116 ◽  
Author(s):  
Valentina Appierto ◽  
Serena Di Cosimo ◽  
Carolina Reduzzi ◽  
Valentina Pala ◽  
Vera Cappelletti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Heterogeneity ◽  
Breast Cancer Case ◽  
Cancer Case ◽  
Circulating Biomarkers

scholarly journals Increased long-term risk of fatal breast cancer in patients with high intra-tumor heterogeneity of the estrogen receptor – Retrospective analyses of the STO-3 trial

2017 ◽  
Vol 28 ◽  
pp. i10
Author(s):  
L.S. Lindström ◽  
C. Yau ◽  
K. Czene ◽  
C. Thompson ◽  
N. Yu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Tumor Heterogeneity

Abstract P1-06-06: Evidence for tumor heterogeneity and clonal evolution during invasive progression of breast cancer

2017 ◽  
Author(s):  
Y Ding ◽  
JR Marks ◽  
LM King ◽  
AH Hall ◽  
ER Mardis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Heterogeneity ◽  
Clonal Evolution
Sign in / Sign up

Export Citation Format

Share Document